246 related articles for article (PubMed ID: 30049557)
1. Real-Life Experience with Pirfenidone in Idiopathic Pulmonary Fibrosis in Argentina. A Retrospective Multicenter Study.
Caro FM; Alberti ML; Campins F; Enghelmayer JI; Fernández ME; Lancellotti D; Papucci T; Sebastiani JA; Paulin F
Arch Bronconeumol (Engl Ed); 2019 Feb; 55(2):75-80. PubMed ID: 30049557
[TBL] [Abstract][Full Text] [Related]
2. Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis.
Vancheri C; Sebastiani A; Tomassetti S; Pesci A; Rogliani P; Tavanti L; Luppi F; Harari S; Rottoli P; Ghirardini A; Kirchgaessler KU; Albera C
Respir Med; 2019 Sep; 156():78-84. PubMed ID: 31445389
[TBL] [Abstract][Full Text] [Related]
3. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.
Tzouvelekis A; Ntolios P; Karampitsakos T; Tzilas V; Anevlavis S; Bouros E; Steiropoulos P; Koulouris N; Stratakos G; Froudarakis M; Bouros D
Pulm Pharmacol Ther; 2017 Oct; 46():48-53. PubMed ID: 28843616
[TBL] [Abstract][Full Text] [Related]
5. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King TE; Bradford WZ; Castro-Bernardini S; Fagan EA; Glaspole I; Glassberg MK; Gorina E; Hopkins PM; Kardatzke D; Lancaster L; Lederer DJ; Nathan SD; Pereira CA; Sahn SA; Sussman R; Swigris JJ; Noble PW;
N Engl J Med; 2014 May; 370(22):2083-92. PubMed ID: 24836312
[TBL] [Abstract][Full Text] [Related]
6. The effects and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis: a meta-analysis and systematic review.
Zang C; Zheng Y; Wang Y; Li L
Eur J Med Res; 2021 Oct; 26(1):129. PubMed ID: 34717762
[TBL] [Abstract][Full Text] [Related]
7. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
[TBL] [Abstract][Full Text] [Related]
8. Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study.
Eaden JA; Barber CM; Renshaw SA; Chaudhuri N; Bianchi SM
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):218-224. PubMed ID: 33093786
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of efficacy and safety of pirfenidone 200 mg tablets in patients with idiopathic pulmonary fibrosis in a real-life setting.
Coşkun F; Çilli A; Hanta İ; Sevinç C; Ödemiş A; Ursavaş A
Turk J Med Sci; 2021 Dec; 51(6):3082-3088. PubMed ID: 34565135
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of pirfenidone for idiopathic pulmonary fibrosis.
Marcos Ribes B; Sancho-Chust JN; Talens A; Arlandis M; Herraiz P; Chiner E; Aznar T
Eur J Hosp Pharm; 2020 Nov; 27(6):350-354. PubMed ID: 33020058
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis.
Ren H; Wang K; Yang H; Gao L
Saudi Med J; 2017 Sep; 38(9):889-894. PubMed ID: 28889145
[TBL] [Abstract][Full Text] [Related]
12. A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study.
Majewski S; Białas AJ; Buchczyk M; Gomółka P; Górska K; Jagielska-Len H; Jarzemska A; Jassem E; Jastrzębski D; Kania A; Koprowski M; Krenke R; Kuś J; Lewandowska K; Martusewicz-Boros MM; Roszkowski-Śliż K; Siemińska A; Sładek K; Sobiecka M; Szewczyk K; Tomczak M; Tomkowski W; Wiatr E; Ziora D; Żołnowska B; Piotrowski WJ
BMC Pulm Med; 2020 May; 20(1):122. PubMed ID: 32366291
[TBL] [Abstract][Full Text] [Related]
13. Deterioration of high-resolution computed tomography findings predicts disease progression after initial decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone.
Higo H; Miyahara N; Taniguchi A; Senoo S; Itano J; Watanabe H; Oda N; Kayatani H; Ichikawa H; Shibayama T; Kajimoto K; Tanimoto Y; Kanehiro A; Maeda Y; Kiura K;
Respir Investig; 2020 May; 58(3):185-189. PubMed ID: 32102769
[TBL] [Abstract][Full Text] [Related]
14. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
[TBL] [Abstract][Full Text] [Related]
15. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena.
Vietri L; Cameli P; Perruzza M; Cekorja B; Bergantini L; d'Alessandro M; Refini RM; Pieroni M; Fossi A; Bennett D; Spalletti M; Mazzei MA; Sestini P; Rottoli P; Bargagli E
Ther Adv Respir Dis; 2020; 14():1753466620906326. PubMed ID: 32066332
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
Okuda R; Hagiwara E; Baba T; Kitamura H; Kato T; Ogura T
Respir Med; 2013 Sep; 107(9):1431-7. PubMed ID: 23849626
[TBL] [Abstract][Full Text] [Related]
17. Pirfenidone treatment of idiopathic pulmonary fibrosis.
Azuma A
Ther Adv Respir Dis; 2012 Apr; 6(2):107-14. PubMed ID: 22333982
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of low dose pirfenidone in idiopathic pulmonary fibrosis: real world experience from a tertiary university hospital.
Song MJ; Moon SW; Choi JS; Lee SH; Lee SH; Chung KS; Jung JY; Kang YA; Park MS; Kim YS; Chang J; Kim SY
Sci Rep; 2020 Dec; 10(1):21218. PubMed ID: 33277557
[TBL] [Abstract][Full Text] [Related]
19. A 2-Year Observational Study in Patients Suffering from Idiopathic Pulmonary Fibrosis and Treated with Pirfenidone: A French Ancillary Study of PASSPORT.
Jouneau S; Gamez AS; Traclet J; Nunes H; Marchand-Adam S; Kessler R; Israël-Biet D; Borie R; Strombom I; Scalori A; Crestani B; Valeyre D; Cottin V
Respiration; 2019; 98(1):19-28. PubMed ID: 30965332
[TBL] [Abstract][Full Text] [Related]
20. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis.
Chaudhuri N; Duck A; Frank R; Holme J; Leonard C
Respir Med; 2014 Jan; 108(1):224-6. PubMed ID: 24269005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]